Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: EDP-125; LY-2216684

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Eddingpharm; Eli Lilly and Company
  • Class Antidepressants; Cyclic ethers; Fluorobenzenes; Morpholines; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Attention-deficit hyperactivity disorder
  • Discontinued Major depressive disorder

Most Recent Events

  • 27 Jun 2023 Eddingpharm plans to submit NDA to the National Medical Products Administration (NMPA) for Attention deficit hyperactivity disorder (ADHD) in China in the second half of 2023 (Eddingpharm pipeline, June 2023)
  • 31 Jan 2023 Phase-III clinical trials in Attention-deficit hyperactivity disorder (In children, In adolescents) in China (PO), prior to January 2023 (Eddingpharm pipeline, June 2023)
  • 31 Jan 2023 Eddingpharm completes a phase-III trial in Attention-deficit hyperactivity disorder (In children, In adolescents) in China (PO) (Eddingpharm pipeline, June 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top